Treatment of ST-segment elevation myocardial infarction during COVID-19 pandemic. [Review]
Citation: Cardiovascular Revascularization Medicine. 21(8):1024-1029, 2020 08.PMID: 32471712Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Betacoronavirus | *Coronavirus Infections/ep [Epidemiology] | *Pandemics | *Percutaneous Coronary Intervention/mt [Methods] | *Pneumonia, Viral/ep [Epidemiology] | *ST Elevation Myocardial Infarction/su [Surgery] | Comorbidity | Coronary Angiography | Humans | ST Elevation Myocardial Infarction/di [Diagnosis] | ST Elevation Myocardial Infarction/ep [Epidemiology]Year: 2020ISSN:- 1878-0938
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 32471712 | Available | 32471712 |
The number of cases of the coronavirus-induced disease-2019 (COVID-19) continues to increase exponentially worldwide. In this crisis situation, the management of ST-segment elevation myocardial infarction (STEMI) is challenging. In this review, we outline the risk and benefits of primary PCI vs. thrombolysis for STEMI. While thrombolysis may seem like a good choice, many patients have a contraindication and could end-up using more resources. Also, with a high probability of the angiogram showing non-obstructed coronary arteries during acute infections, primary PCI should be the preferred strategy. Copyright (c) 2020 Elsevier Inc. All rights reserved.
English